Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Emcure Pharmaceuticals Limited (NSE: EMCURE), ISIN INE168P01015 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
EMCURE last traded at ₹1981.15 (+0.28%), with a 52-week range of ₹1260.10 to ₹2101.00 (as of 23 Sep 2026).
Shareholding as of Jun 2026: promoters 77.83%, FIIs 4.88%, DIIs 8.46%, mutual funds 6.87%.
EquiSense Score (ECS): 77/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.